ABBV last paid $1.73 a share on Oct 19, and returned 27.7% over 12 months with dividends counted. · 1-year total return +27.7% · Track ABBV in a free portfolio

Dividends

Company Overview:

Market Cap: $511.39B
Trailing PE: 49.2x
FWD PE *: 18.1x
Payout Ratio (TTM): 87.6%
52-Week Range: $190.75 - $302.93

* Forward PE is based on street estimates.

10 Year ABBV Performance Metrics:

Total Return (with DRIP): 605% (21.58% CAGR)
Total Return (no DRIP): 465.1% (18.92% CAGR)
Share Price: 385.7% (17.13% CAGR)
Yield on Cost (with DRIP): 17.04%
Total Invested: $10,000
Total Value (with DRIP): $70,465
Total Return $ (with DRIP): $60,465
Dividend Increase: 170.3% (10.73% CAGR)
Dividend Yield (FWD): 2.42% ($6.92)
ABBV 10-yr Total Return ($10K invested)
1M 3M 6M YTD 1Y 3Y 5Y 10Y
ABBV Share Price
1M 3M 6M YTD 1Y 3Y 5Y 10Y All
ABBV Price CAGR:1Y: 24.73%2Y: 30.61%5Y: 19.75%10Y: 16.83%
ABBV Dividend Charts
ABBV - Dividends
ABBV Dividend CAGR:1Y: 5.49%2Y: 5.65%5Y: 5.88%10Y: 11.74%
ABBV - Dividend Payout Ratio
ABBV Dividend Payout Ratio CAGR:1Y: -95.35%2Y: -35.72%5Y: 0.00%10Y: 2.23%
ABBV - Dividend to Free Cash Flow Ratio
ABBV Dividend to FCF Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Build Custom Charts
ABBV - Chart 1
ABBV - Chart 2
ABBV - Chart 3

ABBV Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

Revenue
ABBV Revenue CAGR:1Y: 10.32%2Y: 9.71%5Y: 3.95%10Y: 10.47%
Earnings Per Share (EPS)
ABBV EPS CAGR:1Y: 2,280.00%2Y: 64.46%5Y: 5.98%10Y: 9.39%
Net Income
ABBV Net Income CAGR:1Y: 2,145.74%2Y: 64.46%5Y: 5.84%10Y: 10.20%
EBITDA
ABBV EBITDA CAGR:1Y: 4.30%2Y: 15.22%5Y: 0.15%10Y: 9.30%
Free Cash Flow
ABBV Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Free Cash Flow / Share
ABBV Free Cash Flow / Share CAGR:1Y: 9.97%2Y: 18.45%5Y: -1.12%10Y: 17.50%
Operating Income
ABBV Operating Income CAGR:1Y: 41.43%2Y: 30.09%5Y: 8.53%10Y: 10.63%
Gross Profit
ABBV Gross Profit CAGR:1Y: 41.21%2Y: 20.13%5Y: 8.24%10Y: 11.62%
Shares Outstanding
ABBV Shares Outstanding CAGR:1Y: 0.00%2Y: 0.00%5Y: -0.06%10Y: 0.78%
Share Buybacks
ABBV Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Stock-Based Comp
ABBV Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Expenses
ABBV Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Revenue vs Net Income
EPS vs FCF / Share
EPS vs PE Ratio
FCF vs FCF / Share
FCF vs Stock Based Comp
Cash & Debt
Revenue by Segment
ABBV Revenue CAGR:1Y: 10.32%2Y: 9.71%5Y: 3.95%10Y: 10.47%
Revenue by Region
ABBV Revenue CAGR:1Y: 10.32%2Y: 9.71%5Y: 3.95%10Y: 10.47%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

REVENUE: Actual + Estimates
ABBV Actual Revenue CAGR:1Y: 10.32%2Y: 9.71%5Y: 3.95%10Y: 10.47%
EPS: Actual + Estimates
ABBV Actual EPS CAGR:1Y: 2,280.00%2Y: 64.46%5Y: 5.98%10Y: 9.39%
NET INCOME: Actual + Estimates
ABBV Actual Net Income CAGR:1Y: 2,145.74%2Y: 64.46%5Y: 5.84%10Y: 10.20%
EBITDA: Actual + Estimates
ABBV Actual EBITDA CAGR:1Y: 4.30%2Y: 15.22%5Y: 0.15%10Y: 9.30%

Ratios, Profit Margins & Return on Capital:

Net Profit Margin
ABBV Net Profit Margin CAGR:1Y: 1,954.24%2Y: 49.81%5Y: 1.80%10Y: -0.24%
Gross Profit Margin
ABBV Gross Profit Margin CAGR:1Y: 13.56%2Y: 3.13%5Y: 1.67%10Y: -0.16%
Price to Earnings
ABBV Price to Earnings CAGR:1Y: -95.28%2Y: -29.92%5Y: 12.85%10Y: 5.49%
Price To Sales Ratio
ABBV Price To Sales Ratio CAGR:1Y: 2.41%2Y: 5.00%5Y: 14.88%10Y: 5.23%
Return on Capital Employed
ABBV Return on Capital Employed CAGR:1Y: 197.45%2Y: 25.30%5Y: 10.86%10Y: 3.86%
Return on Invested Capital
ABBV Return on Invested Capital CAGR:1Y: 867.29%2Y: 37.82%5Y: 4.19%10Y: 1.23%

Compare stocks side-by-side

ABBV Dividends Info:

Annual Dividend: $6.92
Forward Yield: 2.42%
Ex-Dividend Date: 2026-10-15
Lifetime Dividends / Share: $59.15

Projected Future Returns & Dividends for ABBV

Based on past 10-year performance, here are ABBV growth metrics:

Share price CAGR of +16.83%
Dividend CAGR of +11.84%

Using ABBV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

ABBV (DRIP)ABBV - No DRIP
Current Price$286.20$286.20
Start Shares34.9434.94
Start Value$10,000$10,000
  
After 10 years:
Final Share Count42.6634.94
Dividends Payment$5.30$5.30
Annual Dividends$904$740
Yield on cost9.04%7.40%
Share Price$1,355.68$1,355.68
Total Dividends$4,765$4,210
Final Value$57,839$51,578

Estimated Future Value + Dividends - ABBV

NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Company Info

AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is traded on NYSE stock exchange.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

ABBV website: https://www.abbvie.com


Loading signals…

DCF Model — ABBV

Value from:
Pay up to today
—
vs current price $286.20
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →